---
title: "Entropy Neurodynamics to Release Escrowed Shares and Options, Boosting Liquidity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287304026.md"
description: "Entropy Neurodynamics Limited will release 49,873,318 shares and unlisted options from escrow on May 29, 2026, enhancing liquidity for investors. The company is advancing its IV psilocin program TRP-8803, targeting hard-to-treat conditions with a focus on psychedelic therapies. Following the escrow expiry, the company will seek quotation for the released shares, increasing flexibility for current and prospective investors."
datetime: "2026-05-22T03:43:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287304026.md)
  - [en](https://longbridge.com/en/news/287304026.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287304026.md)
---

# Entropy Neurodynamics to Release Escrowed Shares and Options, Boosting Liquidity

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Tryptamine Therapeutics ( (AU:ENP) ).

Entropy Neurodynamics Limited, a clinical-stage biotechnology company developing psilocin-based psychedelic therapies, is advancing its lead IV psilocin program TRP-8803 to address limitations of oral psilocybin and leverage positive Phase 2a data in several hard-to-treat conditions. The company targets diseases with unmet medical need and aims to deliver more controllable, commercially practical psychedelic-assisted treatments.

The company has disclosed that 49,873,318 fully paid ordinary shares and a large suite of unlisted options will be released from escrow on 29 May 2026, after which no securities will remain in escrow. Entropy Neurodynamics will seek quotation for the newly released ordinary shares within five business days of the escrow expiry, while any underlying shares issued on future option exercises will be quoted at that time, increasing potential share liquidity and flexibility for existing holders and prospective investors.

**More about Tryptamine Therapeutics**

Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocin administered with psychotherapy to treat diseases with unmet medical needs. Its lead program, TRP-8803, is an intravenous psilocin formulation designed to improve on oral psilocybin by speeding onset, controlling the depth and duration of the psychedelic experience, and shortening treatment sessions to commercially feasible timeframes. Previous Phase 2a trials using oral psilocybin in binge eating disorder, irritable bowel syndrome and fibromyalgia have demonstrated clinical benefits that inform the ongoing development of TRP-8803.

**Average Trading Volume:** 2,299,767

**Technical Sentiment Signal:** Buy

**Current Market Cap:** A$62.01M

For an in-depth examination of ENP stock, go to TipRanks’ Overview page.

## Related News & Research

- [01:01 ETPeproMene Bio anuncia una presentación oral en EHA 2026 donde destacará el PMB-CT01 en linfomas de células B](https://longbridge.com/en/news/288012238.md)
- [<![CDATA[Changing the Standard of Care for Lupus Treatment: Q&A with Albert T. Roy]]>](https://longbridge.com/en/news/287896714.md)
- [MedTherapy bets on low-cost CAR-T manufacturing with Noida CDMO push](https://longbridge.com/en/news/287778163.md)
- [Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | TRAW Stock News](https://longbridge.com/en/news/287773778.md)
- [Acurex Biosciences Awarded ASAP Grant to Advance Breakthrough Approach to Parkinson’s Disease](https://longbridge.com/en/news/287717230.md)